Australian Dry Eye

Click here to edit subtitle

Investors

Atorvastatin. Funding Required: $3-5m for Phase IIb/III
Invention Title: Improvements in Tear Film Stability.

The statin based therapeutic safely and successfully treats both the causes and symptoms of blepharitis and associated dry eye. In many patients, blepharitis co-exists with dry eye and exacerbates patient suffering. Statins have well known cholesterol-lowering and immunomodulatory properties, however the use of statins as a topical ocular therapy for dry eye and blepharitis is novel. The method provides extended break up time to the tear film thus increasing its stability.

Multi-billion dollar market. Full patent coverage in Europe, Australia and Japan. In the process of amendments for the US.

As featured in Insight. Contact: kenneth.ooi@sydney.edu.au